Meeting
2022 ASCO Annual Meeting
Sacubitril-valsartan improves longitudinal strain and ejection fraction in preclinical models treated with anthracyclines through NLRP3, MyD88 pathways resulting in a reduction of myocardial IL-1β, IL-6, TNF-α and growth factors.
Authors
Nicola Maurea
Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”-IRCCS, Naples, Division of Cardiology, Naples, Italy
Nicola Maurea , Martina Iovine , Simona Buccolo , Antonietta Caronna , Carlo Maurea , Annamaria Bonelli , Andrea Paccone , Irma Bisceglia , Maria Laura Canale , Vincenzo Quagliariello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Health Promotion/Behaviors
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12063)
DOI
10.1200/JCO.2022.40.16_suppl.12063
Abstract #
12063
Poster Bd #
309
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Dapagliflozin associated to sacubitril/valsartan and relationship with cardioprotection in human cardiac cells exposed to doxorubicin and HER2-blocking agents through MyD88, NLRP3 mediated pathways.
First Author: Nicola Maurea
Poster
2024 ASCO Breakthrough
Investigation of the effect of macrophage and epithelial cell interaction in the progression of different subtypes of breast cancer.
First Author: Banani Majumdar
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Trastuzumab versus MYL-1401O (a proposed trastuzumab biosimilar) in a phase I bioequivalence study: In vivo and in vitro immunomodulation.
First Author: Régine Audran
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Single-cell cytokine profiling of tumor-infiltrating T cells to measure patient responses to anti-PD-1 therapy.
First Author: Sean Mackay